Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Abstract:
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Research Triangle Park, NC | Posted on January 7th, 2009

"Delivery has been the most significant hurdle to realizing the broad potential of siRNA therapeutics. We are very pleased to form a partnership with Abbott, which we hope will enable significant progress in addressing this problem," said Neal Fowler, Chief Executive Officer of Liquidia. "By combining Abbott's research and development capabilities with Liquidia's particle design and delivery expertise, we hope to enable the use of siRNA for therapy and provide more targeted, effective treatment options for cancer patients."

Under the terms of the agreement, Liquidia will provide Abbott with certain rights to PRINT technology for the development and commercialization of siRNA therapeutics. Financial terms were not disclosed.

About siRNA Therapeutics - Short interfering RNA (siRNA) are small, double stranded RNA molecules that selectively silence and regulate the activity of human genes through the process of RNA interference (RNAi). Since many diseases are caused by the inappropriate expression of certain genes, the ability to selectively silence disease-associated genes represents a novel and powerful method for treating disease. The primary challenge to achieving broad application of siRNA therapeutics is effective delivery of the molecules to target tissues and cell types.

####

About Liquidia Technologies, Inc.
Liquidia Technologies Inc. is a privately-held nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a variety of life and materials science applications. Within life sciences, Liquidia is focused on developing novel vaccines and Engineered Drug Therapies™ for nucleic acid delivery and inhaled therapeutics. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Liquidia Technologies
Elle Pishny
919-328-4361

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for a nanotech self-organizing principle May 1st, 2016

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Nanomedicine

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Announcements

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Patents/IP/Tech Transfer/Licensing

System creates on-demand 'nanotube forests,' has potential industry applications April 20th, 2016

Smaller. Cheaper. Better. Iron nitride transformers developed at Sandia could boost energy storage options March 28th, 2016

Correction: Solar fuels: Protective layer for the 'artificial leaf' March 22nd, 2016

New nanoparticle technology to decipher structure and function of membrane proteins March 9th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016

Leti Extends Collaboration with Qualcomm on CoolCubeTM 3D Integration Technology for High-Density, High-Performance ICs: Collaboration Goals Include Building an Ecosystem To Take the Chip-stacking Technology from Design to Fabrication April 13th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

Strem Chemicals and SONA Nanotech Sign Distribution Agreement for the World’s First Gold Nanorods Synthesized without CTAB February 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic